Matthew Roden - 08 Jan 2026 Form 3 Insider Report for Aktis Oncology, Inc. (AKTS)

Role
President and CEO, Director
Signature
/s/ Matthew Roden
Issuer symbol
AKTS
Transactions as of
08 Jan 2026
Net transactions value
$0
Form type
3
Filing time
08 Jan 2026, 21:05:21 UTC
Previous filing
10 Jun 2022
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
RODEN MATTHEW President and CEO, Director C/O AKTIS ONCOLOGY, INC., 17 DRYDOCK AVENUE, SUITE 17-401, BOSTON /s/ Matthew Roden 08 Jan 2026 0001828130

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AKTS Common Stock 91,998 08 Jan 2026 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AKTS Stock Option (Right to Buy) 08 Jan 2026 Common Stock 578,277 $1.91 Direct F1
holding AKTS Stock Option (Right to Buy) 08 Jan 2026 Common Stock 558,095 $3.66 Direct F2
holding AKTS Stock Option (Right to Buy) 08 Jan 2026 Common Stock 618,757 $9.33 Direct F3
holding AKTS Stock Option (Right to Buy) 08 Jan 2026 Common Stock 394,280 $18.00 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These options have vested in full.
F2 25% of the original number of shares subject to the option vested on November 1, 2023, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.
F3 25% of the original number of shares subject to the option vested on October 9, 2025, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.
F4 25% of the original number of shares subject to the option shall vest on January 8, 2027, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.

Remarks:

Exhibit 24 - Power of Attorney